Backgrounds: Researchers have just commenced the exploration of miRNAs as a prospective new class of biomarkers. This study investigates the potential of miR-1226 as a significant prognostic factor for BC. Methods: The miR-1226 expression was detected in 30 pairs of FFPE tissues using qRT-PCR. The clinicopathological characteristics of patients regarding miR-1226 expression, together with fold change analysis using the 2-ΔΔCT method, were further investigated. All statistical analyses were performed with GraphPad and MedCalc. Results: We found that the miR-1226 level in BC FFPE tissues is slightly increased compared to control tissues. Also, we examined the relationship associated with clinicopathological features and miR-1226 expression levels of BC patients. This investigation revealed no significant association between miR-1226 expression levels and the clinical progression. Age, lymph node involvement, and Ki-67 expression had no significant correlation with outcome status. No significant relationships were observed between tumor-related factors such as grade and size. The hormone receptor status, PR status, and HER-2 status did not exhibit a significant correlation with outcome stratification. The trend regarding PR status may necessitate additional examination for its prognostic significance. Moreover, the p-value, AUC, and Std. Error, sensitivity, and specificity are (p < 0.006, 0.684,0.0723, 83.3, and 60, respectively), which signifies a moderate capacity of the test to differentiate between tumors and controls. The results of fold change analysis employing the 2-ΔΔCT method indicated a (1)-fold elevation in miR-1226 expression in tumors relative to controls. Conclusions: We demonstrated that a slight elevation of miR-1226 expression correlates with the progression of BC, and this indicates that miR-1226 may possess an oncogenic function in BC tumorigenesis and progression.
Shayan Rasheed Abubakir (Wed,) studied this question.